Under the agreement, Abveris will utilize its proprietary DiversimAb mouse model in combination with its next-generation, B-cell screening platform, powered by the Beacon system from Berkeley Lights, to rapidly discover mAbs for use as research reagents and therapeutics for immuno-oncology applications.

The Immunitas team will leverage its single-cell genomics-based techniques for identifying novel therapeutic oncology targets.

Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with...

Integral Molecular adds to its antibody discovery platform
Integral Molecular has developed humanized chicken antibody technology and incorporated it into its MPS antibody discovery platform for multipass membrane...

Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.

Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...